Home

VYNE Therapeutics, Inc. (VYNE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about VYNE Therapeutics, Inc. (VYNE)

Go deeper and ask any question about VYNE

Company Performance

Current Price

as of Sep 13, 2024

$1.84

P/E Ratio

N/A

Market Cap

$27.14M

Description

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

Metrics

Overview

  • HQBridgewater, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerVYNE
  • Price$1.84+2.79%

Trading Information

  • Market Cap$27.14M
  • Float85.93%
  • Average Daily Volume (1m)31,579
  • Average Daily Volume (3m)53,162
  • EPS-$2.57

Company

  • Revenue$0.49M
  • Rev Growth (1yr)46.67%
  • Net Income-$9.40M
  • Gross MarginN/A
  • EBITDA Margin-5,250.51%
  • EBITDA-$10.40M
  • EV$5.89M
  • EV/Revenue12.12
  • P/EN/A
  • P/S161.23
Documents
SEC Filings
8-K (2024-09-12)
8-K (2024-08-14)
8-K (2024-05-09)
8-K (2024-02-29)
8-K (2024-01-03)
8-K (2023-12-13)
8-K (2023-11-13)
8-K (2023-10-30)
8-K (2023-08-14)
8-K (2023-05-11)
8-K (2023-05-01)
8-K (2023-03-09)
8-K (2023-02-28)
8-K (2023-02-10)
8-K (2023-01-17)
8-K (2023-01-12)
10-Q (2024-08-14)
10-Q (2024-05-09)
10-Q (2023-11-13)
10-Q (2023-08-14)
10-Q (2023-05-11)
10-K (2024-03-01)
10-K (2023-03-14)
Earnings Calls
Earnings Report 2021Q3
Earnings Report (2021-11-10)
Factset
Factset Business Description
Factset Street Account
VYNE Therapeutics shareholder AI Biotechnology discloses 20% stake following previously announced private placement - 13D ($3.51, 0.00) (2023-11-13T13:54:57Z)
VYNE Therapeutics reports results from preclinical models for oral BD2-Selective bet inhibitor VYN202 ($2.25, 0.00) (2023-10-30T11:25:04Z)
VYNE Therapeutics reports Q3 EPS ($1.59) ex-items vs year-ago ($2.52) ($3.51, 0.00) (2023-11-13T12:50:06Z)
VYNE Therapeutics discloses preliminary cash balance, termination of previously disclosed purchase agreement with Lincoln Park - 8-K ($2.25, 0.00) (2023-10-30T11:36:46Z)
VYNE Therapeutics announces private placement of $88M through LifeSci Capital ($2.25, 0.00) (2023-10-30T11:07:45Z)
VYNE Therapeutics announced positive data from its Phase 1B trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo ($2.25, 0.00) (2023-10-30T11:06:08Z)